Hôpital Necker-Enfants Malades

Quick facts

Phase 2 pipeline

• Béfizal · Diabetes
  Béfizal is a small molecule that targets the SGLT2 receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Hôpital Necker-Enfants Malades portfolio CI brief
• Hôpital Necker-Enfants Malades pipeline updates RSS

Related

• Sector hub: All tracked pharma companies